Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback Home
Home   COVID-19 treatment studies for Bebtelovimab  COVID-19 treatment studies for Bebtelovimab  C19 studies: Bebtelovimab  Bebtelovimab   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
All Studies   All Outcomes   Recent: 
0 0.5 1 1.5 2+ Mortality -151% Improvement Relative Risk Mortality (b) -201% Hospitalization -27% Hospitalization (b) -51% Hospitalization (c) -2% Viral clearance 36% primary Viral clearance (b) 38% primary Viral clearance (c) 33% primary c19early.com/bt Lilly et al. NCT04634409 Bebtelovimab RCT EARLY TREATMENT Favors bebtelovimab Favors control
Lilly, 380 patient bebtelovimab early treatment RCT: 36% improved viral clearance [p=0.07] https://c19p.org/blaze4
copied to clipboard
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Lilly (Preprint)
12 Feb 2022    Source   PDF   Share   Tweet
RCT with 127 bamlanivimab, etesevimab, and bebtelovimab patients, 125 bebtelovimab patients, and 128 control patients, showing no significant differences in hospitalization and mortality. Viral clearance was improved although not statistically significant. NCT04634409.
risk of death, 150.8% higher, RR 2.51, p = 1.00, treatment 1 of 252 (0.4%), control 0 of 128 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), combined bebtelovimab arms.
risk of death, 200.8% higher, RR 3.01, p = 0.50, treatment 1 of 127 (0.8%), control 0 of 128 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm), bamlanivimab, etesevimab, and bebtelovimab.
risk of hospitalization, 27.0% higher, RR 1.27, p = 1.00, treatment 5 of 252 (2.0%), control 2 of 128 (1.6%), combined bebtelovimab arms.
risk of hospitalization, 51.2% higher, RR 1.51, p = 0.68, treatment 3 of 127 (2.4%), control 2 of 128 (1.6%), bamlanivimab, etesevimab, and bebtelovimab.
risk of hospitalization, 2.4% higher, RR 1.02, p = 1.00, treatment 2 of 125 (1.6%), control 2 of 128 (1.6%), bebtelovimab.
risk of no viral clearance, 35.5% lower, RR 0.64, p = 0.07, treatment 33 of 252 (13.1%), control 26 of 128 (20.3%), NNT 14, day 7 persistently high viral load, combined bebtelovimab arms, primary outcome.
risk of no viral clearance, 38.0% lower, RR 0.62, p = 0.13, treatment 16 of 127 (12.6%), control 26 of 128 (20.3%), NNT 13, day 7 persistently high viral load, bamlanivimab, etesevimab, and bebtelovimab, primary outcome.
risk of no viral clearance, 33.0% lower, RR 0.67, p = 0.18, treatment 17 of 125 (13.6%), control 26 of 128 (20.3%), NNT 15, day 7 persistently high viral load, bebtelovimab, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Lilly et al., 2/12/2022, Randomized Controlled Trial, USA, North America, preprint, 1 author, average treatment delay 3.6 days, trial NCT04634409.
All Studies   All Outcomes
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit